APA

Hu B., Thall P., Milton D. R., Sasaki K., Bashir Q., Shah N., Patel K., Popat U., Hosing C., Nieto Y., Lin P., Delgado R., Jorgensen J., Manasanch E., Weber D., Thomas S., Orlowski R. Z., Champlin R. & Qazilbash M. H. (20200320). High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. : Leukemia & lymphoma.

Chicago

Hu Bei, Thall Peter, Milton Denái R, Sasaki Koji, Bashir Qaiser, Shah Nina, Patel Krina, Popat Uday, Hosing Chitra, Nieto Yago, Lin Pei, Delgado Ruby, Jorgensen Jeffrey, Manasanch Elisabet, Weber Donna, Thomas Sheeba, Orlowski Robert Z, Champlin Richard and Qazilbash Muzaffar H. 20200320. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. : Leukemia & lymphoma.

Harvard

Hu B., Thall P., Milton D. R., Sasaki K., Bashir Q., Shah N., Patel K., Popat U., Hosing C., Nieto Y., Lin P., Delgado R., Jorgensen J., Manasanch E., Weber D., Thomas S., Orlowski R. Z., Champlin R. and Qazilbash M. H. (20200320). High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. : Leukemia & lymphoma.

MLA

Hu Bei, Thall Peter, Milton Denái R, Sasaki Koji, Bashir Qaiser, Shah Nina, Patel Krina, Popat Uday, Hosing Chitra, Nieto Yago, Lin Pei, Delgado Ruby, Jorgensen Jeffrey, Manasanch Elisabet, Weber Donna, Thomas Sheeba, Orlowski Robert Z, Champlin Richard and Qazilbash Muzaffar H. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. : Leukemia & lymphoma. 20200320.